CLINICAL TRIALS PROFILE FOR JANUMET XR
✉ Email this page to a colleague
All Clinical Trials for Janumet Xr
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00532935 ↗ | MK0431A vs. Pioglitazone in Patients With Type 2 Diabetes Mellitus (0431A-066) | Completed | Merck Sharp & Dohme Corp. | Phase 3 | 2008-01-26 | A study to evaluate the efficacy and safety of MK0431A in comparison to a commonly used medication in patients with type 2 diabetes |
| NCT00684528 ↗ | A Double-Blind, Randomized, Active-Comparator (Metformin) Controlled, Clinical Trial to Study the Efficacy and Safety of the Strategy to Start Patients With Type 2 Diabetes Mellitus on Janumet™ Compared to Metformin | Unknown status | Clalit Health Services | Phase 3 | 2008-06-01 | Comparison between the effectiveness of one anti-diabetic drug (Metformin, To combination of this drug and additional drug (Janufer), In the community setting. |
| NCT00684528 ↗ | A Double-Blind, Randomized, Active-Comparator (Metformin) Controlled, Clinical Trial to Study the Efficacy and Safety of the Strategy to Start Patients With Type 2 Diabetes Mellitus on Janumet™ Compared to Metformin | Unknown status | Meir Medical Center | Phase 3 | 2008-06-01 | Comparison between the effectiveness of one anti-diabetic drug (Metformin, To combination of this drug and additional drug (Janufer), In the community setting. |
| NCT00993187 ↗ | Efficacy and Safety of Sitagliptin/Metformin Fixed-Dose Combination (FDC) Compared to Glimepiride in Participants With Type 2 Diabetes Mellitus (MK-0431A-202) | Completed | Merck Sharp & Dohme Corp. | Phase 4 | 2010-05-04 | This study will assess the effect of sitagliptin/metformin FDC 50/1000 mg (Janumet®), MK-0431A) compared with the effect of glimepiride on hemoglobin A1c (HbA1c). The primary hypothesis is that after 30 weeks, sitagliptin/metformin FDC 50/1000 mg provides superior reduction in HbA1c (mean change from baseline) compared to glimepiride. |
| NCT01065766 ↗ | Sitagliptin/Metformin (JANUMET) Re-examination Study (0431A-182) | Completed | Merck Sharp & Dohme Corp. | 2009-03-01 | This survey is conducted for preparing application materials for re-examination under the Pharmaceutical Affairs Laws and its Enforcement Regulation, its aim is to reconfirm the clinical usefulness of sitagliptin/metformin (JANUMET) through collecting the safety and efficacy information according to the Re-examination Regulation for New Drugs. | |
| NCT01269996 ↗ | JanUmet Before Insulin Lantus In Eastern Population Evaluation Program (JUBILEE) In Type 2 Diabetic Patients | Completed | Chinese University of Hong Kong | Phase 4 | 2011-05-01 | To evaluate the efficacy and safety of a new treatment regimen of metformin plus sitagliptin (Janumet) followed by a long-acting basal insulin (Lantus) treatment compared to the usual treatment regimen of metformin followed by sulfonylurea and intermediate-acting basal insulin in Type 2 Diabetes Mellitus patients. |
| NCT01336322 ↗ | Metformin and Sitagliptin in Women With Previous Gestational Diabetes | Completed | Merck Sharp & Dohme Corp. | Phase 2 | 2011-05-01 | The goal of the present research is to compare the effects of treatment with metformin and sitagliptin, alone or in association, in women with previous gestational diabetes to evaluate the impact of the two drugs on beta-cell function. The study results may contribute to give a rational approach for future investigations. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Janumet Xr
Condition Name
Clinical Trial Locations for Janumet Xr
Trials by Country
Clinical Trial Progress for Janumet Xr
Clinical Trial Phase
Clinical Trial Sponsors for Janumet Xr
Sponsor Name
